Antidepressant-like activity of adhyperforin, a novel constituent of Hypericum perforatum L.

Scientific Reports

Volumn 4, Issue , 2014, Pages

  Tian, Jingwei ^a   Zhang, Fangxi ^a   Cheng, Jucan ^a   Guo, Shuren ^b   Liu, Pinglan ^b   Wang, Hongbo ^a  

^a YANTAI UNIVERSITY   (China)

^b PEKING UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADHYPERFORIN; ANTIDEPRESSANT AGENT; DOPAMINE; NORADRENALIN; PLANT EXTRACT; RESERPINE; SEROTONIN; TERPENE;

ANIMAL; ANIMAL BEHAVIOR; CHEMISTRY; DEPRESSION; DRUG EFFECTS; HYPERICUM; IMMOBILIZATION; MALE; METABOLISM; MOTOR ACTIVITY; MOUSE; PHYSIOLOGY; PROCEDURES; RAT; SPRAGUE DAWLEY RAT; SWIMMING;

ANIMALS; ANTIDEPRESSIVE AGENTS; BEHAVIOR, ANIMAL; DEPRESSION; DOPAMINE; HINDLIMB SUSPENSION; HYPERICUM; MALE; MICE; MOTOR ACTIVITY; NOREPINEPHRINE; PLANT EXTRACTS; RATS; RATS, SPRAGUE-DAWLEY; RESERPINE; SEROTONIN; SWIMMING; TERPENES;

EID: 84903957306     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep05632     Document Type: Article

References (34)

1. Monleon, S. et al. Attenuation of sucrose consumption in mice by chronic mild stress and its restoration by imipramine. Psychopharmacology (Berl) 117, 453-457 (1995).
2. Nowak, G. et al. Antidepressant-like effects of acute and chronic treatment with zinc in forced swim test and olfactory bulbectomy model in rats. Brain Res Bull 61, 159-164 (2003). (Pubitemid 36794273)
3. Murray, C. J. & Lopez, A. D. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet 349, 1498-1504 (1997). (Pubitemid 27216360)
4. Marks, D. M., Pae, C. U. & Patkar, A. A. Triple reuptake inhibitors: the next generation of antidepressants. Curr Neuropharmacol 6, 338-343 (2008).
5. Breuer, M.E.etal. The triple monoaminergic reuptake inhibitor DOV 216, 303 has antidepressant effects in the rat olfactory bulbectomy model and lacks sexual side effects. Eur Neuropsychopharmacol 18, 908-916 (2008).
6. Butler, L. & Pilkington, K. Chinese herbal medicine and depression: the research evidence. Evid Based Complement Alternat Med 2013, 739716 (2013).
7. Lieberman, S. A review of the effectiveness of Cimicifuga racemosa (black cohosh) for the symptoms of menopause. J Womens Health 7, 525-529 (1998).
8. Rodriguez-Landa, J. F. & Contreras, C. M. A review of clinical and experimental observations about antidepressant actions and side effects produced by Hypericum perforatum extracts. Phytomedicine 10, 688-699 (2003). (Pubitemid 37500099)
9. Ye, L. et al. Antidepressant-like effects of the extract from Cimicifuga foetida L. J Ethnopharmacol 144, 683-691 (2012).
10. Solomon, D., Ford, E., Adams, J. & Graves, N. Potential of St John's Wort for the treatment of depression: the economic perspective. Aust N Z J Psychiatry 45, 123-130 (2011).
11. Nahrstedt, A. & Butterweck, V. Biologically active and other chemical constituents of the herbof Hypericum perforatumL.Pharmacopsychiatry 30 Suppl2, 129-134 (1997).
12. Chatterjee, S. S., Bhattacharya, S. K., Wonnemann, M., Singer, A. & Muller, W. E. Hyperforin as a possible antidepressant component of hypericum extracts. Life Sci 63, 499-510 (1998). (Pubitemid 28367402)
13. Cervo, L. et al. Role of hyperforin in the antidepressant-like activity of Hypericum perforatum extracts. Psychopharmacology (Berl) 164, 423-428 (2002). (Pubitemid 35439171)
14. Butterweck, V. et al. Step by step removal of hyperforin and hypericin: activity profile of different Hypericum preparations in behavioral models. Life Sci 73, 627-639 (2003). (Pubitemid 36589040)
15. Maisenbacher, P. &Kovar, K.A. Adhyperforin:A HomologueofHyperforin from Hypericum perforatum. Planta Med 58, 291-293 (1992).
16. Nemeroff, C. B. & Owens, M. J. Treatment of mood disorders. Nat Neurosci 5 Suppl, 1068-1070 (2002). (Pubitemid 35247201)
17. Di Carlo, G., Borrelli, F., Ernst, E. & Izzo, A. A. St John's wort: Prozac from the plant kingdom. Trends Pharmacol Sci 22, 292-297 (2001). (Pubitemid 32523912)
18. Nathan, P. J. Hypericum perforatum (St John's Wort): a non-selective reuptake inhibitor? A review of the recent advances in its pharmacology. J Psychopharmacol 15, 47-54 (2001). (Pubitemid 32242103)
19. Muller, W. E., Singer, A., Wonnemann, M., Hafner, U., Rolli, M. & Schafer, C. Hyperforin represents the neurotransmitter reuptake inhibiting constituent of hypericum extract. Pharmacopsychiatry 31 Suppl 1, 16-21 (1998). (Pubitemid 28294221)
20. Willner, P., Muscat, R. & Papp, M. Chronic mild stress-induced anhedonia: a realistic animal model of depression. Neurosci Biobehav Rev 16, 525-534 (1992).
21. Bourin, M., Poncelet, M., Chermat, R. & Simon, P. The value of the reserpine test in psychopharmacology. Arzneimittelforschung 33, 1173-1176 (1983). (Pubitemid 13030321)
22. Bonhomme, N. & Esposito, E. Involvement of serotonin and dopamine in the mechanism of action of novel antidepressant drugs: a review. J Clin Psychopharmacol 18, 447-454 (1998). (Pubitemid 28555327)
23. Belmaker, R. H. & Agam, G. Major depressive disorder. N Engl J Med 358, 55-68 (2008).
24. Bourin, M., Chue, P. & Guillon, Y. Paroxetine: a review. CNS Drug Rev 7, 25-47 (2001). (Pubitemid 32280682)
25. Jensen, A. G., Hansen, S. H. & Nielsen, E. O. Adhyperforin as a contributor to the effect of Hypericum perforatum L. in biochemical models of antidepressant activity. Life Sci 68, 1593-1605 (2001). (Pubitemid 32248716)
26. Wonnemann, M., Singer, A., Siebert, B. & Muller, W. E. Evaluation of synaptosomal uptake inhibition of most relevant constituents of St. John's wort. Pharmacopsychiatry 34 Suppl 1, S148-151 (2001).
27. Gu, L., Liu, Y. J., Wang, Y. B. & Yi, L. T. Role for monoaminergic systems in the antidepressant-like effect of ethanol extracts from Hemerocallis citrina. J Ethnopharmacol 139, 780-787 (2012).
28. Tian, J. W. et al. Preclinical pharmacology of TP1, a novel potent triple reuptake inhibitor with antidepressant properties. Neuroscience 196, 124-130 (2011).
29. Sanchez-Mateo, C. C., Prado, B. & Rabanal, R. M. Antidepressant effects of the methanol extract of several Hypericum species from the Canary Islands. J Ethnopharmacol 79, 119-127 (2002). (Pubitemid 34017250)
30. Papp, M., Gruca, P., Boyer, P. A. & Mocaer, E. Effect of agomelatine in the chronic mild stress model of depression inthe rat. Neuropsychopharmacology 28, 694-703 (2003).
31. Luo, D. D., An, S. C. & Zhang, X. Involvement of hippocampal serotonin and neuropeptide Y in depression induced by chronic unpredicted mild stress. Brain Res Bull 77, 8-12 (2008).
32. Bolden-Watson, C.& Richelson, E. Blockadeby newly-developed antidepressants of biogenic amine uptake into rat brain synaptosomes. Life Sci 52, 1023-1029 ( 1993).
33. Skolnick, P., Popik, P., Janowsky, A., Beer, B. & Lippa, A. S. Antidepressant-like actions of DOV 21, 947: a ''triple'' reuptake inhibitor. Eur J Pharmacol 461, 99-104 (2003). (Pubitemid 36174028)
34. Tatsumi, M., Jansen, K., Blakely, R. D. & Richelson, E. Pharmacological profile of neuroleptics at human monoamine transporters. Eur J Pharmacol 368, 277-283 (1999). (Pubitemid 29117150)